Literature DB >> 11566433

Cannabis induced dopamine release: an in-vivo SPECT study.

L N Voruganti1, P Slomka, P Zabel, A Mattar, A G Awad.   

Abstract

In a research study aimed at examining the alterations in dopaminergic function in schizophrenia, the authors identified a surreptitious case scenario which provided new insights into the subjective and neurochemical effects of cannabis. A 38-year-old drug-free schizophrenic patient took part in a single photon emission computerized tomographic (SPECT) study of the brain, and smoked cannabis secretively during a pause in the course of an imaging session. Cannabis had an immediate calming effect, followed by a worsening of psychotic symptoms a few hours later. A comparison of the two sets of images, obtained before and immediately after smoking cannabis, indicated a 20% decrease in the striatal dopamine D2 receptor binding ratio, suggestive of increased synaptic dopaminergic activity. This observation offers a plausible biological explanation for the psychotogenic effects of cannabis in vulnerable individuals, and also raises speculations about an interaction between cannabinoid and dopaminergic systems in the brain reward pathways.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11566433     DOI: 10.1016/s0925-4927(01)00104-4

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  36 in total

Review 1.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

Review 2.  [Neuroimaging in substance abuse disorders].

Authors:  A de Mendelssohn; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

Review 3.  Legalization, decriminalization & medicinal use of cannabis: a scientific and public health perspective.

Authors:  Dragan M Svrakic; Patrick J Lustman; Ashok Mallya; Taylor Andrea Lynn; Rhonda Finney; Neda M Svrakic
Journal:  Mo Med       Date:  2012 Mar-Apr

Review 4.  Multimodality image registration with software: state-of-the-art.

Authors:  Piotr J Slomka; Richard P Baum
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

5.  Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis.

Authors:  Cheryl M Corcoran; David Kimhy; Arielle Stanford; Shamir Khan; Julie Walsh; Judy Thompson; Scott Schobel; Jill Harkavy-Friedman; Ray Goetz; Tiziano Colibazzi; Victoria Cressman; Dolores Malaspina
Journal:  Schizophr Res       Date:  2008-09-21       Impact factor: 4.939

6.  Orbitofrontal and caudate volumes in cannabis users: a multi-site mega-analysis comparing dependent versus non-dependent users.

Authors:  Yann Chye; Nadia Solowij; Chao Suo; Albert Batalla; Janna Cousijn; Anna E Goudriaan; Rocio Martin-Santos; Sarah Whittle; Valentina Lorenzetti; Murat Yücel
Journal:  Psychopharmacology (Berl)       Date:  2017-04-01       Impact factor: 4.530

7.  CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice.

Authors:  Ramy Khella; Jennifer L Short; Daniel T Malone
Journal:  Psychopharmacology (Berl)       Date:  2014-04-05       Impact factor: 4.530

Review 8.  The effects of Δ9-tetrahydrocannabinol on the dopamine system.

Authors:  Michael A P Bloomfield; Abhishekh H Ashok; Nora D Volkow; Oliver D Howes
Journal:  Nature       Date:  2016-11-17       Impact factor: 49.962

Review 9.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

10.  Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO.

Authors:  Romina Mizrahi; Ivonne Suridjan; Miran Kenk; Tony P George; Alan Wilson; Sylvain Houle; Pablo Rusjan
Journal:  Neuropsychopharmacology       Date:  2012-11-08       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.